KCM
GTHX

Kennedy Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Kennedy Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-72,347
Closed -$357K – 631
2022
Q2 		$357K Sell
72,347
-588
-0.8% -$3.26K 0.01% 565
2022
Q1 		$554K Buy
+72,935
New +$692K 0.01% 550

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kennedy Capital Management's GTHX Position: Q3 2022 in Review

Kennedy Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2022, closing a stake of 72,347 shares — an estimated $357K sold.

Kennedy Capital Management first reported a position in GTHX in Q1 2022 and held it in 2 quarters. The position peaked at $554K in Q1 2022. 104 funds tracked by Wall St. Rank hold GTHX as of Q3 2022.

  • Kennedy Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 72,347 G1 Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $357K.
  • Kennedy Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Kennedy Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $554K in Q1 2022.
  • 104 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Kennedy Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.